Literature DB >> 17587071

Extended-spectrum beta-lactamase-producing Klebsiella spp. in a neonatal intensive care unit: risk factors for the infection and the dynamics of the molecular epidemiology.

K Kristóf1, D Szabó, J W Marsh, V Cser, L Janik, F Rozgonyi, A Nobilis, K Nagy, D L Paterson.   

Abstract

The extended-spectrum beta-lactamase (ESBL)-producing Klebsiella spp. cause worldwide problems in intensive care units. The aim of this study was to investigate the molecular epidemiology of ESBL-producing Klebsiella pneumoniae and K. oxytoca strains in a neonatal intensive care unit (NICU) in Budapest, Hungary and to determine the risk factors of the infections and the epidemiological features. Infections with Klebsiella spp. were analyzed retrospectively by reviewing the medical records between January 2001 and December 2005. Antibiotic susceptibility tests, isoelectric focusing, pulsed field gel electrophoresis, plasmid analysis, PCR for bla(TEM) and bla(SHV) and DNA sequencing analysis were performed on ESBL-producing Klebsiella isolates. A total of 45 babies were found to be infected with non-ESBL-producing Klebsiella spp. and 39 with ESBL-producing Klebsiella spp. Of the parameters analyzed, including sex, gestational age, twin pregnancy, birth weight, presence of central vascular catheter, mechanical ventilator use, parenteral nutrition, polymicrobial infection, caesarean section, transfusion and mortality, we found no statistically significant difference between the ESBL and the non-ESBL groups, or between the K. pneumoniae and K. oxytoca species. Further characterization of the ESBL-producing K. pneumoniae and K. oxytoca strains isolated between February 2001 and January 2003 revealed three distinct PFGE patterns of SHV-5-producing K. pneumoniae (A, B, E) and two distinct patterns of SHV-12-producing K. oxytoca (C,D) isolates; these had different plasmid profiles. From July to November 2005, a new SHV-5 producing K. oxytoca (F) was isolated. The molecular epidemiology of ESBL-producing organisms in a NICU over time shows substantial shifts in predominant strains. The ESBL production of the infected organisms has an impact on the survival of newborn babies with infections caused by Klebsiella spp.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17587071     DOI: 10.1007/s10096-007-0338-9

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  44 in total

1.  Rapid method of extraction and analysis of extended-spectrum beta-lactamases from clinical strains of Klebsiella pneumoniae.

Authors:  D L Paterson; L B Rice; R A Bonomo
Journal:  Clin Microbiol Infect       Date:  2001-12       Impact factor: 8.067

2.  Clonal and horizontal dissemination of Klebsiella pneumoniae expressing SHV-5 extended-spectrum beta-lactamase in a Mexican pediatric hospital.

Authors:  Guadalupe Miranda; Natividad Castro; Blanca Leaños; Adriana Valenzuela; Ulises Garza-Ramos; Teresa Rojas; Fortino Solórzano; Lilia Chihu; Jesús Silva
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

3.  Multiresistant Klebsiella pneumoniae in a neonatal nursery: the importance of maintenance of infection control policies and procedures in the prevention of outbreaks.

Authors:  Y M Coovadia; A P Johnson; R H Bhana; G R Hutchinson; R C George; I E Hafferjee
Journal:  J Hosp Infect       Date:  1992-11       Impact factor: 3.926

4.  Molecular epidemiology as an effective tool in the surveillance of infections in the neonatal intensive care unit.

Authors:  P Villari; L Iacuzio; I Torre; A Scarcella
Journal:  J Infect       Date:  1998-11       Impact factor: 6.072

5.  Klebsiella pneumoniae with extended spectrum beta-lactamase activity associated with a necrotizing enterocolitis outbreak.

Authors:  N Gregersen; W Van Nierop; A Von Gottberg; A Duse; V Davies; P Cooper
Journal:  Pediatr Infect Dis J       Date:  1999-11       Impact factor: 2.129

Review 6.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.

Authors:  F C Tenover; R D Arbeit; R V Goering; P A Mickelsen; B E Murray; D H Persing; B Swaminathan
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

7.  Extended Spectrum Beta-Lactamase-producing Klebsiella pneumoniae outbreaks during a third generation cephalosporin restriction policy.

Authors:  M P Conte; M Venditti; F Chiarini; G D'Ettorre; I Zamboni; G L Scoarughi; C Gallinelli; G B Orsi
Journal:  J Chemother       Date:  2005-02       Impact factor: 1.714

8.  Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome.

Authors:  Bin Du; Yun Long; Hongzhong Liu; Dechang Chen; Dawei Liu; Yingchun Xu; Xiuli Xie
Journal:  Intensive Care Med       Date:  2002-10-17       Impact factor: 17.440

9.  Nosocomial bacteremia and urinary tract infections caused by extended-spectrum beta -lactamase-producing Klebsiella pneumoniae with plasmids carrying both SHV-5 and TLA-1 genes.

Authors:  Dolores Alcantar-Curiel; Juan Carlos Tinoco; Catalina Gayosso; Angeles Carlos; Carlos Daza; Maria C Perez-Prado; Lorena Salcido; Jose I Santos; Celia M Alpuche-Aranda
Journal:  Clin Infect Dis       Date:  2004-03-24       Impact factor: 9.079

10.  Nosocomial spread of ceftazidime-resistant Klebsiella pneumoniae strains producing a novel class a beta-lactamase, GES-3, in a neonatal intensive care unit in Japan.

Authors:  Jun-ichi Wachino; Yohei Doi; Kunikazu Yamane; Naohiro Shibata; Tetsuya Yagi; Takako Kubota; Hideo Ito; Yoshichika Arakawa
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

View more
  8 in total

Review 1.  Extended-spectrum β-lactamase-producing Enterobacteriaceae in children: old foe, emerging threat.

Authors:  Paul J Lukac; Robert A Bonomo; Latania K Logan
Journal:  Clin Infect Dis       Date:  2015-01-16       Impact factor: 9.079

2.  Successful elimination of extended-spectrum beta-lactamase (ESBL)-producing nosocomial bacteria at a neonatal intensive care unit.

Authors:  Borbála Szél; Zsolt Reiger; Edit Urbán; Andrea Lázár; Krisztina Mader; Ivelina Damjanova; Kamilla Nagy; Gyula Tálosi
Journal:  World J Pediatr       Date:  2016-11-23       Impact factor: 2.764

Review 3.  Antibiotic resistance in neonatal intensive care unit pathogens: mechanisms, clinical impact, and prevention including antibiotic stewardship.

Authors:  Sameer J Patel; Lisa Saiman
Journal:  Clin Perinatol       Date:  2010-09       Impact factor: 3.430

4.  Meningitis caused by Escherichia coli producing TEM-52 extended-spectrum beta-lactamase within an extensive outbreak in a neonatal ward: epidemiological investigation and characterization of the strain.

Authors:  Didier Moissenet; Béatrice Salauze; Olivier Clermont; Edouard Bingen; Guillaume Arlet; Erick Denamur; Audrey Mérens; Delphine Mitanchez; Hoang Vu-Thien
Journal:  J Clin Microbiol       Date:  2010-06-02       Impact factor: 5.948

5.  How can the microbiologist help in diagnosing neonatal sepsis?

Authors:  Michela Paolucci; Maria Paola Landini; Vittorio Sambri
Journal:  Int J Pediatr       Date:  2012-01-26

6.  Frequency and characteristics of infections caused by extended-spectrum beta-lactamase-producing organisms in neonates: a prospective cohort study.

Authors:  Nandini Vijayakanthi; Dheeraj Bahl; Nirmaljit Kaur; Arti Maria; Nand Kishore Dubey
Journal:  Biomed Res Int       Date:  2013-09-24       Impact factor: 3.411

Review 7.  Clinical and Molecular Epidemiology of Extended-Spectrum Beta-Lactamase-Producing Klebsiella spp.: A Systematic Review and Meta-Analyses.

Authors:  Tirza C Hendrik; Anne F Voor In 't Holt; Margreet C Vos
Journal:  PLoS One       Date:  2015-10-20       Impact factor: 3.240

8.  Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) for rapid diagnosis of neonatal sepsis.

Authors:  Anusha Rohit; Biswajit Maiti; Shalini Shenoy; Indrani Karunasagar
Journal:  Indian J Med Res       Date:  2016-01       Impact factor: 2.375

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.